The role of miR-29a in the regulation, function, and signaling of liver fibrosis

Ying-Hsien Huang\textsuperscript{a,b}, Ya-Ling Yang\textsuperscript{c}, Feng-Sheng Wang\textsuperscript{d*}

\textsuperscript{a} Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 833

\textsuperscript{b} Department of Pediatrics, Chiayi Chang Gung Memorial Hospital, 613

\textsuperscript{c} Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 833

\textsuperscript{d} Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 833

Running head: MicroRNA-29a in liver fibrosis

Corresponding author:

Feng-Sheng Wang, PhD

Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital

123 Ta-Pei Road, Niao-Sung District, Kaohsiung, Taiwan 833, R.O.C.

Tel: +886-7-7317123 ext. 8795; Fax: +886-7-7338009

E-mail: wangfs@ms33.hinet.net
Abstract

Both fibrosis and cirrhosis of the liver are the end results of most kinds of chronic liver damage and present a common but difficult clinical challenge throughout the world. The inhibition of the fibrogenic, proliferative, and migratory effects of hepatic stellate cells (HSCs) has become an experimental therapy for preventing and even reversing hepatic fibrosis. Furthermore, a complete understanding of the function of non-coding RNA-mediated epigenetic mechanisms in HSC activation may improve our perception of liver fibrosis pathogenesis. This review focuses on an evolving view of molecular mechanisms in which HSC activation by miR-29a signaling may moderate their profibrogenic phenotype, thus supporting the use of miR-29a agonists as a potential therapy for treating liver fibrosis in the future.

Keywords: miR-29a; cholestasis; apoptosis; ER stress; toll like receptors; epigenetics
Persistent liver injury due to cholestasis and hepatitis may cause liver fibrosis, which engages various cell types [1, 2]. Hepatic stellate cells (HSC) are activated and undergo morphologic and functional trans-differentiation, being converted from vitamin A-storing cells into contractile myofibroblastic cells that are responsible for extracellular matrix (ECM) production in injured livers [1-3]. Afterward, the activated form of HSC secretes such profibrogenic mediators as TGF-β signaling and generates ECM components. Fibrosis is morphologically characterized by an increased deposition of extracellular matrix (ECM) proteins, including collagen types I/III, fibronectin, and laminin, all of which can exacerbate the wound-healing process [4]. Fibrillar collagen type I is encoded by collagen-1α1 and collagen-1α2 and accounts for 36% of the total collagens in ECM of healthy livers. In the case of liver fibrogenesis, collagen type I is the predominant isoform deposited in the perisinusoidal space. However, collagen type IV, which constitutes less than 10% of the total collagen in a normal liver, is most dramatically upregulated in fibrosis [5-7]. Mechanisms that regulate ECM gene expression in activated HSCs have become popular as potential therapeutic targets.

1. **miR-29 controls human and murine liver fibrosis and hepatic stellate cell activation**

MicroRNAs (miRNAs) are ~22 nucleotide single-stranded non-coding RNAs
(guide strands) that suppress endogenous mRNA transcripts. Recent studies have shown that levels of miR-29, including miR-29a, miR-29b, and miR-29c, are significantly lower in fibrotic livers, as previously shown in human liver cirrhosis, as well as two different fibrotic animal models (carbon tetrachloride (CCL4) and bile duct ligation (BDL)), while their downregulation affects HSC activation [8-10].

Stimulation of HSC by TGF-β is vital for liver fibrogenesis because of its impact on myofibroblastic transition and ECM induction. TGF-β secreted by hepatocytes, Kupffer cells, and sinusoidal endothelial cells causes HSC to activate, transdifferentiate, and secrete ECM [11]. It is reported that TGF-β1 was capable of mediating the downregulation of miR-29 in HSCs [9]; the same was reported in Bandyopadhyay et al.’s study, who found this effect to be specific to HSC [12]. Furthermore, the overexpression of miR-29 in murine HSC resulted in the down-regulation of collagen expression, including collagen-1α1 and collagen-4α1 [9, 12, 13], by directly targeting these extracellular matrix genes’ mRNA expressions.

2. miR-29a protects against acute liver injury in a mouse model of obstructive jaundice by inhibiting hepatic apoptosis and HSC activation

Through our previous studies [14-18], we have already demonstrated that miR-29a overexpression in cholestatic mice significantly inhibited hepatocellular damage and liver fibrosis; furthermore, it considerably decreased the levels of the
following pro-apoptotic proteins: Bax, phospho-FADD, PARP, cleaved caspase-8, and caspase 3. Overexpression of miR-29a also significantly increased the level of the anti-apoptotic protein phospho-AKT, while significantly decreasing NF-κB, thus causing a significant decrease in hepatocellular injury and hepatocyte apoptosis [14]. Moreover, miR-29a overexpression significantly downregulated phospho-FADD protein expression in the extrinsic apoptotic pathway but did not alter the cytochrome c and X-linked inhibitor of the apoptotic protein, which binds to and inhibits caspase-9 expression in the intrinsic apoptotic pathway [19].

3. miR-29a curtails endoplasmic reticulum stress on cholestatic liver injury

Endoplasmic reticulum (ER) stress, also known as unfolded protein response (UPR), is a harmful reaction caused by the irregular folding of proteins within the ER [20]. Based on the stress type, UPR has been reported to contribute to the survival and apoptosis of cells [20]. In hepatic cells, ER stress has been observed to induce fibrogenic reactions in HSCs by regulating autophagic activities [21]. One study has found that prolonged ER stress increases apoptotic programs and ultimately results in cell death [22], while another observed that inhibiting the IRE1α pathway can maintain the autophagic process and inactive status that allows HSCs to exhibit low fibrogenic activities [21]. Meanwhile, HSCs in the presence of Brefeldin, an ER stress activator, have been observed to increase type
I collagen and Smad 3 expressions in HSCs [23]. Our results have indicated that increased miR-29a expression resulted in the downregulation of IRE1α, PERK, CHOP, and XBP1 in cholestatic livers and HSCs, which then protected against HSC activation and liver fibrosis [17]. We previously uncovered that miR-29a signaling produced inhibitory actions on TGF-β/Smad3-mediated renal fibrosis [24] and liver fibrosis [25]. Altogether, these findings support the hypothesis in our current study that the miR-29a reduction of liver fibrosis is related to the maintenance of ER stress.

4. miR-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation in liver fibrosis

The toll-like receptor (TLR) family is the best characterized class of pattern recognition receptors that signal the host in mammalian species with infection [26]. Typically, Kupffer cells initiate fibrogenesis by secreting proinflammatory and profibrogenic cytokines and activate HSCs to produce an extracellular matrix [27]. TLR2 and 4 are expressed on two key mediators of hepatic fibrogenesis, which are Kupffer cells and HSCs [28]. Mounting evidence has shown that a TLR2 deficiency may protect against CCl4-induced liver fibrosis [29] and that TLR4 can exacerbate cholestatic liver fibrosis [30]. In a recent, we have demonstrated that miR-29a overexpression in cholestatic mice significantly
obstructed TLR2 and TLR4 signaling in liver tissues and significantly decreased their adopter protein, MyD88, and protein expression. It also significantly decreased the proinflammatory cytokines, IL-1β, MCP-1, TGF-β, TNF-α, as well as HMGB1 and p65 expression [18].

5. Epigenetic regulation of genomic DNA and histone in liver fibrosis

The field of epigenetics consists of changing both the chromatin structure and the DNA methylation and acetylation patterns of a genome [31]. Recent studies have found that histone methylation [32] and DNA methylation correlate with HSC activation. DNA methylation represents the classic ‘epigenetic’ mark and is perhaps the best studied epigenetic phenomenon, while the addition of a methyl group on DNA modification is generally related to transcriptional silencing [33]. DNA methylation is established by DNA methyltransferases (DNMTs) called DNMT1, DNMT3A, and DNMT3B [34]. It correlates with converting quiescent HSC into hepatic myofibroblasts, while DNA methylation inhibitors exert epigenetic control over hepatic wound healing and fibrogenesis [32, 35]. Treatment with the DNA methylation inhibitor, 5-aza-2'-deoxycytidine, can mitigate liver fibrosis by upregulating PTEN gene expression and decreasing hypermethylation of the PTEN gene promoter in activated HSCs [36].

Histone methylation on lysine or arginine residues and acetylation also
have a role in regulating transcriptional activities [37]. Typically, the acetylation of histone H3 lysines (H3KAc) correlates with active gene transcription, and H3KAc is mediated by histone acetyl transferases (HATs) and HDAC [38]. Histone deacetylase (HDAC) inhibitors, trichostatin A, and valproic acid have also been observed to be potent inhibitors of HSC activation both \textit{in vitro} and \textit{in vivo} [39, 40].

The histone methyltransferases include mixed-lineage leukemia 1 (MLL1), MLL5, SET1A, and SETDB1, zeste homolog 2 (EZH2) enhancer, and ASH1, while the histone demethylases included KDM1-6 [41]. In the case of HSCs, activation is accompanied by the induction of EZH2 and ASH1 in the transfer of methyl groups to H3K27 (inactive) and H3K4 (active), respectively [42]. Both enzymes have been observed as crucial for maintaining the profibrogenic phenotype of activated HSCs by targeting the peroxisome proliferator-activated receptor gamma (PPAR\(\gamma\)), as well as a number of fibrogenic genes (ASH1), such as collagen I, TIMP1, and \(\alpha\)-SMA [8]. Furthermore, an increasing amount of evidence has established that PPAR\(\gamma\) is a pivotal negative regulator for HSC activation in the pathogenesis of liver fibrosis [43]. Of particular note, SETDB1 can form a corepressor complex that includes NLK (Nemo-like kinase) and represses PPAR\(\gamma\) transactivation via H3K9 methylation [37, 44].
6. Epigenetic regulation of miR-29a in liver fibrosis

We have previously demonstrated that miR-29a normalizes HDAC4 expression and increases the acetylation status of H3K9 in HSCs [15]. However, histone methylation is reversible, and its dynamic nature is controlled by a balance between histone methyltransferases and histone demethylases [41] so it may be associated with either active or inactive gene promoters in accordance with the position of the modified lysine. Furthermore, miR-29a overexpression reduced the expression of fibrotic genes, HDAC4 signaling, and HSC migration and proliferation. In contrast, the knockdown of miR-29a with an antisense inhibitor increased HDAC4 function, restored HSC migration, and accelerated HSC proliferation [15]. Our research team has also found HDAC4 interference to increase the acetylation status of H3K9, which is enriched in the miR-29a proximal promoter and reduces miR-29a transcription in high glucose-stressed podocytes [24]. On the other hand, miR-29a overexpression promotes nephrin acetylation, which improves hyperglycemia-induced podocyte dysfunction by inhibiting HDAC4 signaling transduction [24].

DNA methylation is related to the transformation of HSCs into hepatic myofibroblasts. Treatment with DNA methylation inhibitors modulates epigenetic reactions, subsequently mitigating hepatic wound healing and fibrogenesis [32,
Our results have indicated that miR-29a overexpression resulted in significant reductions in DNMT1, DNMT3b, and SET1A protein expressions in affected livers [45], as well as the hypomethylation status of DNA in HSCs.

7. Additional studies regarding miR-29a in liver fibrosis

Bioinformatics searches suggest that SETDB1 has been established as a putative miR-29a target (http://microrna.sanger.ac.uk and www.microrna.org). Therefore, we can assume that miR-29a can transactivate PPARγ expression by targeting SETDB1 and hypomethylation of H3K9. One recent study has demonstrated that histone H3K9 demethylase, JMJD1A, or KDM3A can act as a novel epigenetic regulator in modulating HSC activation and liver fibrosis by targeting PPARγ gene expression [46]. miR-29a has notably been shown to be capable of suppressing prostate cell proliferation and induce apoptosis by regulating KDM5B proteins [47]. Furthermore, HNF-4α can maintain hepatocyte identity by regulating miR-29a and -29b expression, which can subsequently control epigenetic modifications by limiting DNMT3A and DNMT3B levels. In fact, bioinformatics searches have suggested that MLL5, DNMT3A, and DNMT3B have been established as putative miR-29a targets (http://microrna.sanger.ac.uk and www.microrna.org) (below) and that DNMT3B is involved in PPARG suppression [8].
8. Conclusion

Liver fibrosis and cirrhosis are the end results of most kinds of chronic liver damage and represent a common but difficult clinical challenge. Therefore, the inhibition of the fibrogenic phenotype of HSCs is emerging as an experimental therapy for preventing and even reversing hepatic fibrosis. Proper knowledge of the function of miR-29a’s genetic and epigenetic mechanisms in HSC activation may improve our understanding of liver fibrosis pathogenesis (Figure 1). Mounting evidence has highlighted that a miR-29a precursor will be an innovative therapeutic potential for liver fibrosis in the future.
Figure 1. The proposed genetic and epigenetic mechanism of miR-29a in the mitigation of liver fibrosis. miR-29a is a crucial regulator of the profibrogenic phenotype of HSCs. Increased miR-29a function hinders ER stress, TLR 2, 4, HDAC4 and methyltransferases signaling, thus inhibiting the activation of HSCs.

Declaration of Conflict of Interest

The authors hereby declare to have no financial interests or conflicts of interest to disclose in relation to this article.

Acknowledgments
The authors would like to thank Miss Yuan-Ting Chuang and Chia-Ling Wu for assisting with this article.

**Funding:** This study was supported by grants from the National Health Research Institute (NHRI-EX107-10736SI), Ministry of Science and Technology, Taiwan (106-2314-B-182A-141 -MY3) and Chang Gung Memorial Hospital, Taiwan (CMRPG8G1341, and 8F1562). However, these organizations had no part in the study design, data collection and analysis, publication decisions, or preparation of the manuscript.
References


